TABLE 6.
The performances of cross-validations on THCA and lung cancer samples.
| THCA (170) a | Lung (184) | |||
|---|---|---|---|---|
| K-fold | Nested | K-fold | Nested | |
| ACC | 0.843 ± 0.017 b | 0.817 ± 0.010 | 0.786 ± 0.020 | 0.741 ± 0.010 |
| SEN | 0.773 ± 0.025 | 0.706 ± 0.021 | 0.697 ± 0.035 | 0.679 ± 0.026 |
| SPE | 0.892 ± 0.035 | 0.910 ± 0.016 | 0.848 ± 0.025 | 0.783 ± 0.019 |
| AUC | 0.925 ± 0.010 | 0.909 ± 0.007 | 0.841 ± 0.014 | 0.806 ± 0.011 |
ACC, accuracy; SEN, sensitivity; SPE, specificity; AUC, area under the receiver operating characteristic curve; THCA, thyroid cancer.
a
Each group of samples was a mix of cancer and control samples (n = 260).
b
The results show 95% confidence intervals for all the validations (totally 50 validations for each cross-validation).